India’s CDMO Sector Poised for Growth as Global Pharma Diversifies Beyond China

The global pharmaceutical supply chain is undergoing a seismic shift as multinational drugmakers seek to reduce their dependence on China. As regulatory scrutiny intensifies around major Chinese players like WuXi AppTec, Indian Contract Development and Manufacturing Organisations (CDMOs) are emerging as the primary beneficiaries of this strategic realignment.

India Emerges as the Preferred Alternative to China

The transition away from Chinese manufacturing is not a sudden reaction to recent geopolitical tensions but a trend that began nearly two years ago. According to Sivaramakrishnan Chittor, CFO of Sai Life Sciences, global pharmaceutical companies have already been engaging in active dialogues with Indian CDMOs to diversify their manufacturing footprints.

The inclusion of Indian entities in critical regulatory and trade lists has provided the necessary clarity for global firms to move forward. This shift is being driven by a desire for supply chain resilience and risk mitigation. Indian companies are proactively responding to this "landmark opportunity" by scaling up operations and committing significant capital expenditure (Capex) to meet rising global demand.

Sai Life Sciences: Scaling Up with Strategic Investments

A key indicator of this industry-wide optimism is the aggressive expansion planned by major players. Sai Life Sciences has announced plans to invest between ₹1,100 crore and ₹1,300 crore in capacity expansion by FY27. This investment will be funded through a combination of internal accruals and debt, leveraging the company's currently strong, low-debt balance sheet.

While new production facilities are expected to become operational by the end of the current financial year, management notes that reaching optimal capacity utilization will be a gradual process. Despite the long-term outlook, the company maintains a steady revenue growth guidance of 15-20% CAGR, acknowledging that the complex regulatory nature of pharmaceutical manufacturing means contract transfers take time.

Shifting Revenue Mix and the Rise of Commercial Manufacturing

The changing landscape is clearly visible in the revenue structures of leading Indian firms. Over the past four years, Sai Life Sciences has seen its revenue contribution from global big pharma companies jump from 28% to 49%. This highlights a deeper integration of Indian manufacturers into the core value chains of the world's largest drugmakers.

Furthermore, there is a fundamental shift in how India is utilized in the drug development lifecycle. Historically, many global companies used Indian CDMOs primarily for clinical trial supplies. However, there is a growing trend toward using India for large-scale commercial manufacturing. This is evidenced by the increase in Phase III and pre-registration molecules; for instance, Sai Life Sciences reported an increase from six to eleven such molecules, signaling growing confidence in India's ability to handle commercial-scale production.

Key Takeaways

• Strategic Diversification: Global pharma companies are actively moving manufacturing away from China toward India to mitigate regulatory and supply chain risks.
• Massive Capex Deployment: Leading Indian CDMOs, such as Sai Life Sciences, are investing upwards of ₹1,100 crore to expand capacity to meet long-term demand.
• Evolution of Capability: India is transitioning from a provider of clinical supplies to a critical hub for large-scale, commercial-grade pharmaceutical manufacturing.